Nevro’s HFX iQ spinal cord stimulator earned the European Union’s CE mark, the company said Nov. 12.
HFX iQ has already earned FDA approval in 2022, according to a news release. The spinal cord stimulator uses artificial intelligence combined with high-frequency therapy to help patients with chronic pain. It is indicated for back and leg pain, non-surgical refractory back pain, painful diabetic neuropathy, chronic upper limb and neck pain.
The company plans to launch the system in select European countries in early 2025.
Centinel Spine, a global medical device company, reported a 33% increase in year-over-year revenue during the first quarter of 2025. …
Aurora Spine reported $17.6 million in revenue during fiscal year 2024, an increase of more than 20% over the previous…
Globus Medical CEO Daniel Scavilla’s salary rose to $4.8 million in 2024, according to the company’s April 25 Securities and…
Comments are closed.